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Abstract
Although the pathogenic mechanisms that underlie autism are not well understood, there is evidence showing that
metabotropic and ionotropic glutamate receptors are hyper-stimulated and the GABAergic system is hypo-stimulated in
autism. Memantine is an uncompetitive antagonist of NMDA receptors and is widely prescribed for treatment of Alzheimer’s
disease treatment. Recently, it has been shown to improve language function, social behavior, and self-stimulatory
behaviors of some autistic subjects. However the mechanism by which memantine exerts its effect remains to be
elucidated. In this study, we used cultured cerebellar granule cells (CGCs) from Fmr1 knockout (KO) mice, a mouse model for
fragile X syndrome (FXS) and syndromic autism, to examine the effects of memantine on dendritic spine development and
synapse formation. Our results show that the maturation of dendritic spines is delayed in Fmr1-KO CGCs. We also detected
reduced excitatory synapse formation in Fmr1-KO CGCs. Memantine treatment of Fmr1-KO CGCs promoted cell adhesion
properties. Memantine also stimulated the development of mushroom-shaped mature dendritic spines and restored
dendritic spine to normal levels in Fmr1-KO CGCs. Furthermore, we demonstrated that memantine treatment promoted
synapse formation and restored the excitatory synapses to a normal range in Fmr1-KO CGCs. These findings suggest that
memantine may exert its therapeutic capacity through a stimulatory effect on dendritic spine maturation and excitatory
synapse formation, as well as promoting adhesion of CGCs.
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Introduction
Autism is the most severe of a group of neurodevelopmental
disorders referred to autism spectrum disorders (ASDs), and is
characterized by problems in communication, social skills, and
repetitive behavior. Susceptibility to autism is attributable to
genetic factors [1,2,3,4], but the exact cause of this disorder is not
yet known. There is some evidence showing that metabotropic and
ionotropic glutamate receptors are affected in autism. Purcell et al
[5] demonstrated that there is excessive glutaminergic activity in
autistic brain. A normal level of glutamate is important for
neurotransmitters that play a key role in long-term potentiation,
learning and memory [6,7,8,9]. Hypo-function of the inhibitory
GABAergic system and hyperactivity of the excitatory glutamate
system has been theorized to have a causal role in autism [10].
Memantine is a low-affinity voltage-dependant uncompetitive
antagonist at NMDA receptors [11,12], as shown in Figure 1. It is
widely prescribed for the treatment of Alzheimer’s disease (AD).
Studies have shown that memantine can be rapidly displaced from
the NMDA receptor, which may avoid prolonged receptor
blockade and the associated detrimental effects on learning and
memory [13]. In addition, memantine has been demonstrated to
act as an antagonist at nicotinic acetylcholine receptors and at 5-
HT receptors [14,15]. Both in vitro and in vivo studies indicate that
memantine offers protective effects from neurotoxicity and can
improve learning and memory in several preclinical models of AD
[16,17,18,19]. Perry et al [20] reported decreased nicotinic
receptors and decreased cholinergic receptors in the cortices of
autistic brain. Several studies have reported beneficial results with
the utilization of cholinesterase inhibitors in AD to enhance frontal
lobe function and promote executive language and social response
in autism [21,22,23]. Most recently, two small open-label studies
reported the effect of memantine on improving language and
behavior of autistic subjects [24,25]. In a large scale clinical trial
study involving 151 subjects, Chez et al [26] further observed that
open-label use of memantine significantly improved language
function, social behavior, and self-stimulatory behaviors of autistic
subjects. Studies are underway with memantine and larger
numbers of autistic subjects (Clinicaltrials.gov). In addition,
Erickson et al [27] reported that 4 of 6 patients with Fragile X
syndrome (FXS) and a co-morbid diagnosis of pervasive develop-
mental disorder (PDD) with memantine treatment showed global
clinical benefit on ratings with the Clinical Global Impressions-
Improvement subscale (CGI-I). However the cellular mechanism
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36981by which memantine improves language and social behaviors in
autism remains to be elucidated.
In this study, we examined the effects of memantine on the
cultured cerebellar granule cells (CGCs) from Fmr1 knockout
(Fmr1-KO) mice, which is a mouse model for FXS and currently
also used as a mouse model for autism studies [28,29,30]. Our
results show that the maturation of dendritic spines is delayed in
Fmr1-KO CGCs. We also detected reduced excitatory synapse
formation in Fmr1-KO CGCs. Memantine treatment of Fmr1-KO
CGCs promoted cell adhesion properties. Memantine also
stimulated the development of mushroom-shaped dendritic spines
and restored dendritic spine to normal levels seen in Fmr1-KO
CGCs. Furthermore, we demonstrate that memantine treatment
promoted synapse formation and restored the excitatory synapses
to a normal range in Fmr1-KO CGCs.
Methods
Fmr1 knockout mice
Mice were from a colony of congenic C57BL/6 fragile X mice
derived from C57BL/6-129 hybrid mice carrying the Fmr1
knockout mutation originally provided through the generosity of
B. Oostra, P.Willems and S.Warren. Offspring of mice that
carried the knockout mutation were distinguished from their
normal siblings by polymerase chain reaction (PCR) analysis with
1.5 mM MgCl2 and using S1, S2 primers for the normal allele and
M2, N2 primers for the knockout allele essentially as originally
described [28]. All experiments with live animals conformed to the
guidelines for the ethical use of animals of the NYS Institute for
Basic Research in Developmental Disabilities Institutional Animal
Care and Use Committee (IACUC).
Cell culture and memantine treatment
CGCs were prepared from wild type (WT) and Fmr1 KO 5–6
day postnatal pups as described previously [31]. Briefly, the entire
cerebellum was dissected out, and single cell suspensions were
prepared by trypsinization and trituration in 1% trypsin in Ca
2+-
free isotonic phosphate buffer (CF-PBS). Cells were washed in CF-
PBS and resuspended in culture medium (MEM), supplemented
with 0.25% glucose, 2 mM glutamine, 10% HS, 5% FCS, and
both penicillin and streptomycin. Cells were seeded into poly-D-
lysine-coated dishes and incubated at 37uC in a moist chamber
under 5% CO2. After 24 hr in vitro the medium was replaced with
serum-free medium containing 15% N-2 supplement and 15 mM
KCl in the medium. After 5–7 days in vitro (DIV) CGCs were used
for the experiments reported in the present study. When required,
the CGCs were treated for 72 h with memantine (Sun Pharma) at
a concentration of 100 mM, referred from the literature [32,33].
Cell adhesion assay
Approximately 10,000 CGCs were plated per well in 96 well
tissue culture plates coated with poly-D-lysine (Sigma-Aldrich) at a
final concentration of 10 mg/ml. After 1.5 h of attachment,
unattached cells were removed by aspiration and adherent cells
were quantified by the colorimetric aqueous MTS assay (CellTiter
96 AQueous One Solution kit, Promega).
Cell migration assay
CGCs were labeled with fluorescent Calcein AM (BD Biosci-
ences) at a final concentration of 2.5 mM. Approximately 10,000
labeled cells were plated in 0.8 ml DMEM +1% FBS in each well
of a 24 well chamber plate adapted for the HTS Fluoroblock (BD
Falcon) apparatus. After 3 h, 5% FBS was added to the lower
chamber medium to establish a 1–5% serum gradient and
migration of cells from the upper to lower chamber were
quantified at 2 h using a microfluorimetric plate reader (CytoFluor
4000, MTX Lab Systems) [34].
DiI labeling
The culture was labeled using a protocol adapted from Hering et
al [35] Briefly, CGCs were fixed in 4% formaldehyde for 15 min
and incubated with Vybrant-DiI cell-labeling solution (1:200,
Invitrogen) for 25 min at 37uC. Cultures were washed in warmed
PBS, incubated in PBS at 4uC for 24–48 hr to allow dye diffusion
within membranes, mounted on glass slides with ProLong Gold
antifade reagent (Invitrogen), and then imaged using a Nikon
Eclipse E800 microscope. Spines were classified according to
previously described criteria [36,37]: the mushroom type has a
large head with short neck; the stubby type has a short protrusion
with no clear neck; the thin type has a long neck and a small head.
Spine length was measured from shaft to tip using a bent-line tool
[38]. The spines were counted in 12–18 neurons/group from the
independent experiments. For each neuron, 1–4 dendrites were
analyzed. The spine value was averaged in each independent
experiment for the statistical test. The n value refers to the number
of independent experiments analyzed.
Immunofluorescence
CGCs were fixed in 4% formaldehyde for 15 min and blocked
with 3% goat serum/0.3% Triton X-100 in PBS and incubated
with an anti-Syp polyclonal antibody (anti-synaptophysin, 1:200,
Cell Signaling Technology), anti-VGLUT1 monoclonal antibody
(1:500, Millipore), and anti-VGAT polyclonal antibody (1:500,
Millipore) overnight at 4uC, followed by incubation with Alexa
Fluor 488 anti-rabbit IgG and Alexa Fluor 555 anti-mouse IgG
(1:1000, Invitrogen) for 1.5 h at room temperature. Cell number
and distribution were analyzed following staining with nuclear
marker Hoechst 33258 (Sigma-Aldrich) for 5 min at room
temperature. Cultures were mounted on glass slides with ProLong
Gold antifade reagent (Invitrogen), and imaged using a Nikon
Eclipse E800 microscope.
The analysis of immunofluorescent images was done as
described previously [39]. Images were acquired in the linear
range with constant settings and analyzed using Image J software
(National Institutes of Health, Bethesda, MD, USA). All analyses
were performed blind as to the treatment of the culture.
Immunoreactive puncta were defined as discrete regions along
the dendrite with fluorescence intensity twice the background and
average size of the puncta were normalized with data from the
Figure 1. Schematic representation of memantine and NMDA
receptor.
doi:10.1371/journal.pone.0036981.g001
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from two to three different batches of cultures and experiments for
each condition were randomly chosen on the basis of having a
healthy morphology. Negative controls, in which the primary
antibodies were omitted and treated only with the secondary
antibodies, were run for each condition to exclude false positive
secondary antibody binding. The n value refers to the number of
cells analyzed.
Statistics
The statistical analyses were carried out by one-way analysis of
variance (ANOVA) with Fisher’s PLSD post hoc test using the
StatView 5.0 software (SAS Institute, Inc.). The Kolmogorov-
Smirnov test was used to compare the two distributions. All data is
presented as means 6 SE. Significance was accepted at p,0.05 or
better.
Results
Memantine promotes CGCs adhesion
To test the effect of memantine on adhesion of CGCs, Fmr1-KO
and WT CGCs were seeded on the PDL-coated surface. Cell
adhesion was evaluated by a modified MTS assay based on
dehydrogenase conversion of MTS to colored tetrazolium salt, a
reaction that is mediated only by viable cells. The amount of
colored product formed at 490 nm (OD 490) was proportional to
the number of attached cells. As shown in Figure 2, there was an
increase in cell adhesion in Fmr1-KO CGCs compared to WT
CGCs (one-way ANOVA, F=22.42, p,0.0001; Fisher’s PLSD,
p=0.03), and after treatment with memantine, Fmr1-KO CGCs
exhibited a 19% increase in adhesion (Fisher’s PLSD, p=0.002).
Figure 2. Memantine increased the adhesion property in Fmr1-
KO CGCs. Comparison of CGCs adhesion. The values are mean 6SE
from three independent experiments with five replicates in each
experiment,
*p,0.05,
**p,0.01. OD: optical density.
doi:10.1371/journal.pone.0036981.g002
Figure 3. Memantine had little effect on CGCs migration. A. Cultured CGCs. Scale bar, 100 mm. B. CGCs stained with Calcein AM dye in
modified Boyden chamber migration assay. Scale bar, 100 mm. C. Comparison of CGCs migration. The values are mean 6SE from three independent
experiments with five replicates in each experiment. AFU: arbitrary fluorescence units.
doi:10.1371/journal.pone.0036981.g003
The Therapeutic Effect of Memantine in Autism
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36981Memantine has little effect on CGCs migration
Cell migration is modulated by a complex of adhesion
molecules interacting between migrating cells and the surrounding
extracellular matrix proteins, and is critically affected by cell
adhesion [40]. Since we observed that memantine promotes CGC
adhesion, we further investigated whether memantine affects CGC
migration with a modified Boyden chamber assay [34]. This assay
enabled us to count the cells migrating through the insert into
lower chamber. Our results indicated that memantine has little
effect on CGCs migration as we observed no significant difference
in cell migration in comparing WT CGCs, Fmr1-KO CGCs and
Fmr1-KO CGCs treated with memantine (one-way ANOVA,
F=0.70, p=0.52, Figure 3).
Memantine treatment restores dendritic spine to normal
levels in Fmr1-KO CGCs
Dendritic spine dynamics plays an important role in mediating
learning and memory, and is of essential importance to synaptic
function [41,42]. To test whether memantine treatment affected
the development of dendritic spines, DiI labeling was employed to
outline the shape of dendritic spines (Figure 4A). Our results
showed that the density of mushroom-shaped mature dendritic
spines was significantly decreased in Fmr1-KO CGCs as compared
with WT CGCs (one-way ANOVA, F=7.86, p=0.02; Fisher’s
PLSD, p,0.01, Figure 4B). However, treatment with memantine
stimulated the development of dendritic spines and restored the
density of mushroom-shaped spines in Fmr1-KO CGCs to the
normal level (Fisher’s PLSD, p=0.02, Figure 4B). We examined
the effects of memantine on spine length and found that dendritic
spines were longer in Fmr1-KO CGCs than in WT CGCs (one-
way ANOVA, F=31.43, p,0.0001; Fisher’s PLSD, p=0.03).
Memantine decreased the spine length in Fmr1-KO CGCs
(Fisher’s PLSD, p,0.0001, Figure 4C). In addition, the distribu-
tion of different length of spines was altered after memantine
treatment (Figure 4D). Fmr1-KO CGCs exhibited fewer short
spines and more medium to long spines (Kolmogorov-Smirnov
Comparison, p=0.01), while more short spines were present in
memantine-treated Fmr1-KO CGCs as compared with Fmr1-KO
CGCs without treatment (Kolmogorov-Smirnov Comparison,
p,0.0001).
Memantine stimulates synapse formation and restores
the excitatory synapses to a normal range in KO CGCs
To further investigate the effects of memantine on synapse
formation, using antibodies to synaptic vesicle proteins we
examined synapse formation comparing WT CGCs, Fmr1-KO
CGCs and Fmr1-KO CGCs treated with memantine. We stained
the CGCs with antibodies to synaptophysin (a general marker of
all synapses) and to the vesicular glutamate transporter VGLUT1
and the vesicular GABA transporter VGAT (markers of excitatory
and inhibitory synapses respectively). We observed a dramatic
decrease in the immunoreactivity of excitatory synapses
(VGLUT1 staining) in Fmr1-KO CGCs as compared with that
in WT CGCs (one-way ANOVA, F=5.44, p=0.01; Fisher’s
PLSD, p=0.01, Figure 5). Memantine treatment significantly
stimulated excitatory synapse formation in Fmr1-KO CGCs
Figure 4. Memantine restored dendritic spine to normal levels in Fmr1-KO CGCs. A. Cultured CGCs were stained with Vybrant-DiI to outline
the shape of dendritic spines. Arrows colored in white show the mushroom-shaped spines, while arrows colored in yellow show the thin-shaped
spines, Scale bars, 10 mm. Histogram showed the density of mushroom-shaped spines (B), spine length (C) and cumulative frequency distribution of
spine lengths (D) in WT CGCs, Fmr1-KO CGCs and Fmr1-KO CGCs treated with memantine. The data are the mean 6 SE,
*p,0.05,
**p,0.01. n=3.
doi:10.1371/journal.pone.0036981.g004
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of excitatory synapse to the level observed in WT CGCs (Figure 5).
In addition, we found that the intensities of total synapses (Syp
staining) and inhibitory synapses (VGAT staining) were not altered
in Fmr1-KO CGCs as compared with that in WT CGCs (one-way
ANOVA, F=25.52, p,0.0001; Fisher’s PLSD, p=0.58, Figure 6
and one-way ANOVA, F=10.53, p=0.001; Fisher’s PLSD,
p=0.95, Figure 7, respectively). Memantine treatment also
stimulated the formation of total synapses and inhibitory synapses
in Fmr1-KO CGCs (Fisher’s PLSD, p,0.0001, Figure 6 and
p=0.001, Figure 7, respectively). The ratio of excitatory to
inhibitory synapses in Fmr1-KO CGCs was lower than in WT
CGCs (one-way ANOVA, F=4.70, p=0.02; Fisher’s PLSD,
p=0.04). However, memantine treatment did not change the ratio
in Fmr1-KO CGCs (Fisher’s PLSD, p=0.52, Figure 7).
Discussion
The hypo-function of the GABAergic system and the glutamate
toxicity found in autism have been implicated as possibly having a
causal role for autism [5,20]. Memantine is an uncompetitive
antagonist at NMDA receptors [11,12] and is widely used for the
treatment of AD. Memantine has been demonstrated to have
neuroprotective effects and promote neurogenesis [43,44]. Most
recently, several clinical trials have reported that memantine can
significantly improve language function and social behavior of
patients with autism and fragile X syndrome (FXS) [24,25,26,27].
Neuroanatomical studies on autistic individuals have revealed loss
of purkinje and granule cells of the cerebellum [45,46] and
cerebellar dysfunction in animal models can induce autism-like
behavioral deficits [47,48]. Granule cells of the cerebellum
constitute the largest homogeneous neuronal population of
mammalian brain. Due to their postnatal generation and the
feasibility of well characterized primary in vitro cultures, cerebellar
granule cells (CGCs) are a model of choice for the study of neural
development, function and pathology [49]. In this study, using
cultured CGCs from Fmr1-KO, we first examined how memantine
affects the cell properties. We found that memantine significantly
promoted the adhesion of CGCs, while having little effect on the
cell migration.
Integrin-mediated cell adhesion has been shown to be essential
in the regulation of neuronal migration, which is a critical process
that determines the final location of neurons, and thus establishes
the basis for neural circuits [40,50,51,52]. In addition, the
complexity and specificity of synaptogenesis relies upon regulation
of cell adhesion molecules that mediate contact initiation, synapse
formation and plasticity. Disruption of adhesion could result in an
imbalance in the structure and function of synapses [53,54].
Recently, several lines of studies have shown that mutations in the
synaptic adhesion molecules Neurexin 1 and Neuroligins 3 and 4
are associated with autism [54,55]. Mutations in scaffolding
molecule Shank3 that interacts with Neuroligins have also been
Figure 5. Memantine fully restored the intensity of excitatory synapses to a normal range in Fmr1-KO CGCs. Representative
photomicrographs of labeling of VGLUT1 (arrow) in WT CGCs, Fmr1-KO CGCs and Fmr1-KO CGCs treated with memantine. Red, VGLUT1; Blue,
Hoechst, scale bars, 25 mm. The histogram shows quantification of puncta size using image analysis. WT, n=23; Fmr1-KO, n=25; Fmr1-
KO+Memantine, n=26.
*p,0.05.
doi:10.1371/journal.pone.0036981.g005
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imply that a defect in synaptic cell adhesion may alter synapse
formation, maturation and plasticity in autistic subjects. Since
memantine promotes CGC adhesion, we reason that it could play
a role in the regulation of neural synaptogenesis. Thus, memantine
might counteract some of the defects in synaptic cell adhesion
molecules found in autism. In our study, we found that the
adhesion of Fmr1-KO CGCs was increased as compared with
controls. Whether there is a defect in adhesion-associated
molecules in Fmr1-KO mice or FXS patients is unknown and
our results suggest that it is of important significance to further
investigate synaptic cell adhesion and migration properties in FXS
in the future.
Our study further demonstrated that memantine stimulated
synapse formation. In particular, memantine restored the number
of excitatory synapses found in Fmr1-KO CGCs to the level of that
in the WT CGCs. Synapses critically mediate neuronal commu-
nication. The number, type, and connectivity patterns of synapses
determine the formation, maintenance, and function of neural
circuitries [58]. Recently, Yun and Trommer [59] reported that
that the peak amplitude of NMDA receptor-mediated excitatory
postsynaptic currents (EPSCs) was smaller in Fmr1-KO mice as
compared with controls, while AMPA receptor-mediated EPSCs
were comparable in the two groups. In addition, they found
diminished medial perforant path-granule cell long-term potenti-
ation (LTP), complementing previous findings that demonstrated
impaired LTP in CA1, neocortex, and amygdala and exaggerated
long-term depression in CA1 of Fmr1-KO mice [60]. We suggest
that the stimulatory effect of memantine on excitatory synapse
formation could counter the smaller EPSCs found in Fmr1-KO
CGCs and exert a therapeutic role. However whether memantine
can actually promote excitatory synaptic transmission remains to
be further studied.
In addition, we found that memantine also stimulated the
formation of inhibitory synapses. Thus memantine treatment did
not change the ratio of excitatory to inhibitory synapses. This
leaves open the question of whether memantine affects the neural
circuit balance. Future studies will be needed to answer this
question. The stimulatory effect of memantine on both excitatory
and inhibitory synapse formation suggests that memantine may
have a general role in promoting neurogenesis. Recently, several
studies have shown that memantine promotes cell proliferation
and production of mature granule neurons in the adult hippo-
campus [43,61]. Memantine has also been demonstrated to
stimulate the proliferation of hippocampal progenitor cells [62].
All these findings imply that memantine can play a role in
neurogenesis.
To further elucidate the role of memantine on neural
development and function, we examined dendritic spines. We
showed that memantine treatment promotes the development of
mature (mushroom-shaped) dendritic spines and can restore the
dendritic spine to normal levels in Fmr1-KO CGCs. Several
categories of spines have been identified based on their shape and
size, including thin, stubby, cup, and mushroom shaped [63].
Spine morphology is linked to synapse function and the
mushroom-shaped spines considered to represent the most mature
Figure 6. Memantine stimulated the formation of total synapses in Fmr1-KO CGCs. Representative photomicrographs of labeling of Syp
(arrow) in WT CGCs, Fmr1-KO CGCs and Fmr1-KO CGCs treated with memantine. Green, Syp; Blue, Hoechst, scale bars, 25 mm. The histogram shows
quantification of puncta size using image analysis. WT, n=23; Fmr1-KO, n=25; Fmr1-KO+Memantine, n=26.
**p,0.01.
doi:10.1371/journal.pone.0036981.g006
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excitatory synapses mainly connect to mushroom-shaped dendritic
spines [65]. Thus, the increase in mushroom-shaped spines in
response to memantine treatment is consistent with our findings
that memantine stimulates the formation of excitatory synapses.
The effect of memantine on spines in Fmr1-KO CGCs also
suggests a role of memantine in restoring synaptic transmission.
A number of studies have reported defects of dendritic spines in
Fmr1-KO mice [38,66]. It has been reported that the length of
dendritic spines, a measure of immaturity, is increased in Fmr1-
KO mice, suggesting a delay in the development of dendritic
spines. In our study, we found that the length of dendritic spines
was significantly impaired in Fmr1-KO CGCs, which is supportive
of the findings from Nimchinsky et al [66]. The effect of
memantine in enhancing dendritic spine maturation could
contribute to its observed therapeutic effects in autistic and FXS
patients. We reckon there could be two ways memantine exert its
restoring role in FMRP deficient neurons. It could specifically
counteract the loss of FMRP and therefore only acting on those
dendritic spines that are immature as a result of FMRP loss.
Alternatively memantine could have a more general effect on the
development and maturation of dendritic spines and not directly
target those neurons altered by the loss of FMRP. Studies will be
carried out on wild type mice to further elucidate the mechanism
Figure 7. Memantine stimulated the formation of inhibitory synapses in Fmr1-KO CGCs. Representative photomicrographs of labeling of
VGAT (arrow) in WT CGCs, KO CGCs and KO CGCs treated with memantine. Green, VGAT; Blue, Hoechst, scale bars, 25 mm. The histogram shows
quantification of puncta size using image analysis and ratio of excitatory synapses to inhibitory synapse. WT, n=23; Fmr1-KO, n=25; Fmr1-
KO+Memantine, n=25.
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0036981.g007
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formation and dendritic spine maturation.
In summary, we have shown that Fmr1-KO CGCs exhibit
delayed development of dendritic spines and reduced excitatory
synapse formation. Memantine treatment of Fmr1-KO CGCs
promoted cell adhesion. Memantine also stimulated the develop-
ment of mushroom-shaped dendritic spines and restored the
dendritic spine to normal levels in Fmr1-KO CGCs. Furthermore,
we demonstrated that memantine treatment can enhance synapse
formation, particularly excitatory synapses and it restored the
excitatory synapses to a normal range in Fmr1-KO CGCs. These
findings suggest that the stimulatory effect of memantine on
dendritic spines development and excitatory synapse formation, as
well as the adhesion promoting effect could be mechanisms by
which memantine exerts its therapeutic effect in autism and FXS.
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